GET DAILY SIGNALSCardiol Therapeutics (CRDL) Q3 2026 Earnings: Pipeline and Cash Runway in Focus
Key Takeaways
- Cardiol Therapeutics (CRDL) is set to report third-quarter fiscal 2026 results for the three months ended September 30, 2026, on or around November 12, 2026.
- As a pre-revenue clinical-stage biopharmaceutical firm, Cardiol has no meaningful product sales, so attention will center on net loss per share, research spending, and cash position.
- Consensus estimates call for a net loss of about $0.07 to $0.08 per share, after a narrower-than-expected $0.04 loss in the prior quarter.
- The Phase III MAVERIC trial of CardiolRx in recurrent pericarditis has met its original enrollment goal and is expanding, with topline data now expected in mid-2027.
- Warrant exercises recently brought in more than $7 million, extending the cash runway into the first half of 2028.
- For more on CRDL's Major News, Today's Price Move, Price Targets, and Forecast, check the dedicated pages for updates.
- Review Trending AI Robots to see AI-driven trading strategies attracting attention.
Why This Earnings Update Matters
Cardiol Therapeutics (CRDL) is a late-stage life sciences company focused on anti-inflammatory and anti-fibrotic therapies for heart disease. With no approved products yet, its quarterly reports emphasize pipeline advancement and capital management over sales figures. The main driver continues to be the Phase III MAVERIC trial of CardiolRx, an oral cannabidiol solution, for recurrent pericarditis. In September 2026 the company said it had hit the 110-patient target ahead of schedule and would expand to as many as 150 patients, moving topline data to mid-2027. This earnings release offers a check on spending discipline, trial progress, and the status of the extended cash runway.
What Analysts Expect
Analysts anticipate a net loss of roughly $0.07 to $0.08 per share for the third quarter, with estimates varying more widely. Revenue remains effectively zero, as expected for a company without a commercial product. In the second quarter Cardiol posted a $0.04 loss per share, beating the roughly $0.09 consensus, and it has met or exceeded expectations in several recent periods. With negligible top-line results, investors will focus on research and development expenses linked to the MAVERIC trial, general and administrative costs, and the cash balance that management has indicated will support operations into the first half of 2028. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and Investor Focus
Sentiment ahead of the report is driven more by clinical developments than by the income statement. The stock has tended to react to trial milestones and financing updates. The late-September 2026 announcement of expanded MAVERIC enrollment and the shift in topline timing to mid-2027 added an important consideration, while the longer cash runway offered reassurance. For this quarter, the key questions are whether research spending aligns with expectations, whether management confirms the updated clinical timeline, and whether any further details emerge on enrollment or the broader pipeline, including the subcutaneous candidate CRD-38 for heart failure.
Looking Ahead
The main catalyst remains the Phase III MAVERIC readout now slated for mid-2027 after the enrollment expansion to up to 150 patients. Management has stated that current cash should cover the trial through completion and into early 2028, which lowers near-term financing concerns even as dilution stays a factor for a pre-revenue biotech. Progress on CRD-38, the subcutaneous formulation for heart failure, will also be worth tracking as it moves toward investigational new drug-enabling studies. Any updates on regulatory strategy for a potential New Drug Application submission to the FDA, assuming positive MAVERIC results, will draw attention. On the financial side, quarterly cash burn and the trajectory of research and development spending remain central. A measured spending approach that sustains the runway while supporting trial momentum would be viewed positively. Clinical-stage companies carry meaningful binary risk, and the ultimate value of the pipeline will depend on data showing meaningful benefit in recurrent pericarditis and eventually in broader inflammatory heart disease.
Using AI Tools in My Research Process
I find Tickeron’s AI Screener particularly useful when evaluating clinical-stage biotechs like Cardiol. It lets me quickly filter for comparable names by industry, market cap, technical patterns, and AI-driven signals, which helps put quarterly updates into broader context without spending hours on manual screening. The tool has become a regular part of how I review pipeline-focused names and monitor sector shifts.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CRDL's Indicator enters downward trend
The Aroon Indicator for CRDL entered a downward trend on November 11, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 185 similar instances where the Aroon Indicator formed such a pattern. In 175 of the 185 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CRDL as a result. In 85 of 100 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRDL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CRDL's RSI Oscillator exited the oversold zone, 19 of 23 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 65 of 71 cases where CRDL's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Moving Average Convergence Divergence (MACD) for CRDL just turned positive on October 23, 2026. Looking at past instances where CRDL's MACD turned positive, the stock continued to rise in 43 of 50 cases over the following month. The odds of a continued upward trend are 86%.
Following a +11.17% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRDL advanced for three days, in 178 of 220 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
CRDL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 22 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 56 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.032) is normal, around the industry mean (6.379). P/E Ratio (-2.926) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (183.387).
The Tickeron Price Growth Rating for this company is 76 (best 1 - 100 worst), indicating slightly worse than average price growth. CRDL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRDL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PharmaceuticalsGeneric
Advertisement